Danish health authorities said on Monday they would ask the European Union's drug regulator to review the findings of two ...

Danish pharmaceutical firm Novo Nordisk A/S (NYSE:NVO) announced plans to invest approximately $1.20 billion (8.5 billion ...

Ozempic maker Novo Nordisk A/S is investing 8.5 billion kroner ($1.2 billion) to build a new major factory in Denmark to help ...

Danish drugmaker Novo Nordisk will invest 8.5 billion crowns ($1.20 billion) in a new facility in Odense, Denmark, for the ...

The weight-loss drugs battle has grabbed Wall Street's attention and stoked shares of Eli Lilly and Novo Nordisk. But others ...

Novo Nordisk announced on Thursday that a key European Medicines Agency committee has backed a label update for weight-loss ...

EU regulator supports a label expansion of Novo Nordisk’s diabetes drug to reflect its potential to lower the risk of ...

The European Medicines Agency (EMA) will allow Novo Nordisk to add risk reduction for events related to kidney disease to the ...

NVO's CagriSema target of up to 25% in long-term weight loss is highly promising vs. 15% through Wegovy and 20% through ...

Danish pharma company Novo Nordisk, makers of weight-loss drugs Ozempic and Wegovy, plans to expand production based on a ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...